Drugs / Beclomethasone Dipropionate/Formoterol Fumarate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05292586 | Aug 2022 → Jun 2024 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Beclomethasone Dipropionate/Formoterol Fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05292586 ↗ |
| Known as | CHF 1535 | “CHF 1535 pMDI = 200/6 μg pressurised metered dose inhaler (fixed combination of extrafine beclomethasone dipropionate [BDP] plus formoterol fumarate [FF]).” NCT05292586 ↗ |
| Route | Inhaled | “After a two-week run-in period with asthma maintenance therapy switched to BDP via pressurized metered-dose inhaler (pMDI), eligible patients were randomized to BDP/FF or BDP,...” PMID 41231513 ↗ Nov 2025 |